Antares Pharma, Inc. (ATRS)

[Dimensions]

One thing that concerned me about ATRS last press release about Bioavailability is below in bold. ATRS said what happened in the 1 instance of TEAE in the oral group. However they did not say what the other 4 TEAE were, which you assume were in the subcutaneous group.

Treatment in both the oral methotrexate and subcutaneous methotrexate arms of the study were generally well tolerated. Five patients (10.2 percent) had a treatment-emergent adverse event; one patient in the oral MTX group experienced mild and transient nausea. Some patients in the delivery device group had slight to barely perceptible erythema at the injection site after administration. No patients experienced bleeding, ecchymosis, or hematoma at the injection site or required countermeasures during the study. No patients discontinued the study because of an injection site reaction.

While I don't think this is a real concern, if someone knows what the other 4 TEAEs were I would appreciate knowing. If the other 4 incidents were the erythema they should have just point blank stated that.